Yesterday, the European Parliament approved a proposal to allow waivers of supplementary protection certificates (SPCs) for EU generics and biosimilars by a vote of 572 to 36.
Yesterday, the European Parliament approved a proposal to allow waivers of supplementary protection certificates (SPCs) for EU generics and biosimilars by a vote of 572 to 36.
An SPC is an intellectual property right that grants an extension of up to 5 years on a 20-year patent term for an innovative drug. The goal of the SPC is to offset the loss of patent protection that occurs during the development and clinical trials of a generic or biosimilar. When implemented in 1992, the SPC system sought to provide the pharmaceutical industry with sufficient incentives to develop innovative products within the European Union and to prevent companies from relocating to other countries.
Under the newly approved proposal, an SPC waiver will allow EU biosimilar developers and generics makers to manufacture products that are protected by SPCs (while the SPCs are still in force) if the manufacturing is conducted to facilitate export to a non-EU market where there is no protection of the original medicine.
The new rule will also allow companies to stockpile products during the last 6 months of an SPC’s term in order to allow for a day-1 launch of these products in the EU market after the SPC’s protection expires.
Generic and biosimilar makers will be required to notify authorities before they start production of their products, meet labeling obligations to ensure that their products are not diverted to the European Union, and inform their supply chains that the products cannot be sold in the EU market before the day-1 entry.
The rule will next be formally adopted by EU ministers and published in the EU Official Journal. The rule is expected to come into force in July 2019, after which companies will be permitted to begin manufacturing under the waiver from July 2022.
Medicines for Europe (MFE), a generic and biosimilar trade group, commended the European Union for adopting the waiver. Adrian van den Hoven, director general of MFE, said in a statement that the “vote on the SPC manufacturing waiver reflects the EU’s commitment to access to medicines, manufacturing jobs in Europe and putting EU industry on a level playing field globally. Europe has everything to gain from fully implementing the waiver to enable more competition on the pharmaceutical market and to improve its own security of medicines supply.”
The European Federation of Pharmaceutical Industries and Associations (EFPIA), however, said in its own statement on the vote that the new rule will negatively impact innovator companies’ ability to develop new therapies and that it “sends a negative signal to the world that Europe is devaluing its intellectual property framework, making Europe a less attractive location for research and development, impacting on jobs and investment.”
EFPIA called on the commission to “redress the balance” by fast-tracking breakthrough therapies and supporting research and development opportunities.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.